Gene expression in chronic granulomatous disease and interferon‐γ receptor‐deficient cells treated in vitro with interferon‐γ

Interferon‐γ (IFN‐γ) plays an important role in innate and adaptive immunity against intracellular infections and is used clinically for the prevention and control of infections in chronic granulomatous disease (CGD) and inborn defects in the IFN‐γ/interleukin (IL)‐12 axis. Using transcriptome profiling (RNA‐seq), we sought to identify differentially expressed genes, transcripts and exons in Epstein‐Barr virus–transformed B lymphocytes (B‐EBV) cells from CGD patients, IFN‐γ receptor deficiency patients, and normal controls, treated in vitro with IFN‐γ for 48 hours. Our results show that IFN‐γ increased the expression of a diverse array of genes related to different cellular programs. In cells from normal controls and CGD patients, IFN‐γ‐induced expression of genes relevant to oxidative killing, nitric oxide synthase pathway, proteasome‐mediated degradation, antigen presentation, chemoattraction, and cell adhesion. IFN‐γ also upregulated genes involved in diverse stages of messenger RNA (mRNA) processing including pre‐mRNA splicing, as well as others implicated in the folding, transport, and assembly of proteins. In particular, differential exon expression of WARS (encoding tryptophanyl‐transfer RNA synthetase, which has an essential function in protein synthesis) induced by IFN‐γ in normal and CGD cells suggests that this gene may have an important contribution to the benefits of IFN‐γ treatment for CGD. Upregulation of mRNA and protein processing related genes in CGD and IFNRD cells could mediate some of the effects of IFN‐γ treatment. These data support the concept that IFN‐γ treatment may contribute to increased immune responses against pathogens through regulation of genes important for mRNA and protein processing.

[1]  Vassilios Ioannidis,et al.  Avoiding the pitfalls of gene set enrichment analysis with SetRank , 2017, BMC Bioinformatics.

[2]  Xuetao Cao,et al.  Cellular and molecular regulation of innate inflammatory responses , 2016, Cellular & Molecular Immunology.

[3]  Alexander Dobin,et al.  Mapping RNA‐seq Reads with STAR , 2015, Current protocols in bioinformatics.

[4]  R. Wilson,et al.  Open‐label pilot study of interferon gamma‐1b in Friedreich ataxia , 2015, Acta neurologica Scandinavica.

[5]  O. Yeǧin,et al.  In vitro interferon γ improves the oxidative burst activity of neutrophils in patients with chronic granulomatous disease with a subtype of gp91phox deficiency , 2015, Central-European journal of immunology.

[6]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[7]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[8]  Ariel Miller,et al.  Gene Expression Profiling of the Response to Interferon Beta in Epstein-Barr-Transformed and Primary B Cells of Patients with Multiple Sclerosis , 2014, PloS one.

[9]  L. Santos‐Argumedo,et al.  Innate defects of the IL-12/IFN-γ axis in susceptibility to infections by mycobacteria and salmonella. , 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[10]  J. B. Oliveira,et al.  ICON: The Early Diagnosis of Congenital Immunodeficiencies , 2014, Journal of Clinical Immunology.

[11]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[12]  W. Huber,et al.  Detecting differential usage of exons from RNA-seq data , 2012, Genome research.

[13]  I. Condò,et al.  Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model , 2012, Human molecular genetics.

[14]  S. Holland.  Chronic granulomatous disease. , 2013, Hematology/oncology clinics of North America.

[15]  A. Towbin,et al.  Chronic granulomatous disease , 2010, Pediatric Radiology.

[16]  A. Dembińska-kieć,et al.  Evidence for potential functionality of nuclearly-encoded humanin isoforms. , 2009, Genomics.

[17]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[18]  Guillaume Vogt,et al.  Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations , 2005, Nature Genetics.

[19]  T. Mizukami,et al.  Clinical evaluation of interferon-gamma treatment to chronic granulomatous disease patients with splice site mutations. , 2004, Japanese journal of infectious diseases.

[20]  Jianping Pan,et al.  Interferon-γ is an autocrine mediator for dendritic cell maturation , 2004 .

[21]  T. Ellis,et al.  Interferon‐γ activation of polymorphonuclear neutrophil function , 2004 .

[22]  K. Schroder,et al.  Interferon- : an overview of signals, mechanisms and functions , 2004 .

[23]  M. Newport,et al.  Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. , 2004, Lancet.

[24]  J. Reader,et al.  Biologically active fragment of a human tRNA synthetase inhibits fluid shear stress-activated responses of endothelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Bonnefoy,et al.  Interferon-γ switches monocyte differentiation from dendritic cells to macrophages , 2003 .

[26]  M. Gerstein,et al.  Genomic and proteomic analysis of the myeloid differentiation program: global analysis of gene expression during induced differentiation in the MPRO cell line. , 2002, Blood.

[27]  P. Schimmel,et al.  A human aminoacyl-tRNA synthetase as a regulator of angiogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Schimmel,et al.  A fragment of human TrpRS as a potent antagonist of ocular angiogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Gerstein,et al.  Genomic and proteomic analysis of the myeloid differentiation program. , 2001, Blood.

[30]  T. Mizukami,et al.  Improved superoxide-generating ability by interferon gamma due to splicing pattern change of transcripts in neutrophils from patients with a splice site mutation in CYBB gene. , 2001, Blood.

[31]  S. Ikehara,et al.  Differential Regulation of Human Blood Dendritic Cell Subsets by IFNs1 , 2001, The Journal of Immunology.

[32]  R. B. Johnston,et al.  Clinical aspects of chronic granulomatous disease. , 2001, Current opinion in hematology.

[33]  P. Newburger,et al.  Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of chronic granulomatous disease due to a splice site consensus region mutation , 2000 .

[34]  R. Döffinger,et al.  In a novel form of IFN-gamma receptor 1 deficiency, cell surface receptors fail to bind IFN-gamma. , 2000, The Journal of clinical investigation.

[35]  Richard B. Johnston,et al.  Chronic Granulomatous Disease: Report on a National Registry of 368 Patients , 2000, Medicine.

[36]  P. Newburger,et al.  Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of chronic granulomatous disease due to a splice site consensus region mutation. , 2000, Blood.

[37]  J. Weiner,et al.  Novel Dendritic Kinesin Sorting Identified by Different Process Targeting of Two Related Kinesins: KIF21A and KIF21B , 1999, The Journal of cell biology.

[38]  P. Newburger,et al.  NADPH oxidase activity and cytochrome b558 content of human Epstein-Barr-virus-transformed B lymphocytes correlate with expression of genes encoding components of the oxidase system. , 1998, Archives of biochemistry and biophysics.

[39]  L. Zentilin,et al.  Nicotinamide-adenine dinucleotide phosphate oxidase assembly and activation in EBV-transformed B lymphoblastoid cell lines of normal and chronic granulomatous disease patients. , 1998, Journal of immunology.

[40]  K. Starko,et al.  Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. , 1995, Blood cells, molecules & diseases.

[41]  A. Tolstrup,et al.  Transcriptional Regulation of the Interferon--inducible Tryptophanyl-tRNA Synthetase Includes Alternative Splicing (*) , 1995, The Journal of Biological Chemistry.

[42]  E. Böttger,et al.  Molecular cloning and characterization of an interferon induced human cDNA with sequence homology to a mammalian peptide chain release factor. , 1992, The EMBO journal.

[43]  J. Fleckner,et al.  Human interferon gamma potently induces the synthesis of a 55-kDa protein (gamma 2) highly homologous to rabbit peptide chain release factor and bovine tryptophanyl-tRNA synthetase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. van Marck,et al.  Endogenous IFN-gamma is required for resistance to acute Trypanosoma cruzi infection in mice. , 1991, Journal of immunology.

[45]  S. Orkin,et al.  Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. , 1989, The New England journal of medicine.

[46]  S. Orkin,et al.  Partial Correction of the Phagocyte Defect in Patients with X-Linked Chronic Granulomatous Disease by Subcutaneous Interferon Gamma , 1988 .

[47]  H. Binz,et al.  Modulation of Major Histocompatibility Complex (MHC) Expression by Interferons and Microbial Agents , 1988, Scandinavian journal of immunology.

[48]  P. Newburger,et al.  Cellular and molecular effects of recombinant interferon gamma in chronic granulomatous disease. , 1988, Hematology/oncology clinics of North America.

[49]  K. Petroni,et al.  Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-gamma and glucocorticoids. , 1988, Journal of immunology.

[50]  G. Trinchieri,et al.  Immune interferon enhances functional properties of human granulocytes: role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor. , 1987, Journal of immunology.

[51]  A. Fauci,et al.  B cell lines as models for inherited phagocytic diseases: abnormal superoxide generation in chronic granulomatous disease and giant granules in Chediak-Higashi syndrome. , 1984, Journal of immunology.

[52]  C. Nathan,et al.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity , 1983, The Journal of experimental medicine.